- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Hassan on the Rationale for Examining Talazoparib Plus Carboplatin in TNBC
April 14th 2021, 12:31pm
Saima Hassan, MD, PhD, FRCSC, discusses the rationale for examining talazoparib in combination with carboplatin in patients with triple-negative breast cancer.
Dr. Subbiah on the Efficacy of Selpercatinib in RET Fusion–Positive Cancers
April 13th 2021, 11:30pm
Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.
Neoadjuvant Cemiplimab Elicits Complete Pathological Responses in HCC
April 13th 2021, 10:26pm
Significant tumor necrosis was observed in 20% of patients with resectable hepatocellular carcinoma who received neoadjuvant treatment with cemiplimab-rwlc.
Trastuzumab Deruxtecan Benefit/Risk Profile in Advanced Cancer Supported by Pooled Analysis
April 13th 2021, 6:47pm
The majority of independently adjudicated interstitial lung disease cases associated with fam-trastuzumab deruxtecan-nxki were low grade and occurred within the first 12 months of treatment, with lower risk of developing the effect observed in patients who were on the drug for longer than 1 year.
Atezolizumab Induces Durable Activity Irrespective of MSI Status in Advanced Solid Tumors With TMB ≥16 Mut/Mb
April 13th 2021, 5:44pm
Atezolizumab elicited durable clinical activity irrespective of microsatellite instability status in patients with advanced solid tumors with a tumor mutational burden of more than 16 mutations per megabase.
AFM13 Showcases 100% ORR in Relapsed/Refractory CD30+ Hodgkin Lymphoma
April 13th 2021, 3:30pm
AFM13, an innate cell engager, demonstrated an objective response rate of 100% in adult patients with CD30-positive, relapsed/refractory Hodgkin lymphoma.
Multi-Omics Approach to Personalized Therapy Shows Feasibility in Metastatic Breast Cancer
April 13th 2021, 2:54pm
A multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data has demonstrated feasibility in patients metastatic breast cancer vs DNA sequencing alone.
Telisotuzumab Vedotin Demonstrates Efficacy and Tolerability in Previously Treated c-MET+ NSCLC
April 13th 2021, 1:05pm
Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer.
Talazoparib Most Likely to Induce Response in mCRPC With Germline and/or Homozygous tDDR Alterations
April 13th 2021, 12:53pm
Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.
D-0316 Shows Encouraging Efficacy in EGFR T790M+ NSCLC Subsets
April 12th 2021, 11:15pm
Treatment with D-0316 demonstrated encouraging clinical activity in select patients with EGFR T790M-positive non–small cell lung cancer who progressed on prior therapy.
Twice-Daily Poziotinib Improves Efficacy, Tolerability in EGFR- or HER2 Exon 20–Positive NSCLC
April 12th 2021, 9:00pm
Administering the investigational TKI poziotinib at a twice-daily dose compared with once-daily dosing showed a reduction in both grade 3 or higher treatment emergent adverse effects and dose interruptions, as well as improved efficacy in patients with EGFR- or HER2 exon 20–positive non–small cell lung cancer.
Talazoparib Plus Carboplatin Induces Synergistic Activity in Multiple TNBC Cell Lines
April 12th 2021, 7:55pm
The combination of the PARP inhibitor talazoparib and carboplatin demonstrated synergistic activity in 7 cell lines of triple-negative breast cancer, with greater DNA damage and cell death observed in PARP inhibitor–resistant cell lines and at lower concentrations of talazoparib when combined with carboplatin.
Dabrafenib Plus Trametinib Provides Benefit Across Glioma Subtypes
April 12th 2021, 7:10pm
Dual inhibition of the MAPK pathway using the BRAF and MEK inhibitors dabrafenib and trametinib, respectively, resulted in durable clinical benefit for patients with BRAF V600E mutant low- and high-grade glioma.
Dr. Gorlick on the Use of Integrative Surfaceome Profiling to Identify Targets in Osteosarcomas
April 12th 2021, 6:51pm
Richard Gorlick, MD, discussed results from a study examining the use of integrative surfaceome profiling to identify immunotherapeutic targets in patients with osteosarcomas.
Adavosertib/Irinotecan Shows Early Activity in Pediatric Neuroblastoma
April 12th 2021, 5:34pm
Adavosertib plus irinotecan showed early activity in a cohort of pediatric patients with neuroblastoma, thus meeting the protocol-defined efficacy end point of the 1/2 ADVL1312 trial.
Novel Combinations Under Study in Advanced RCC
April 12th 2021, 4:50pm
The activity and safety of investigational combinations will be subject to study in patients with advanced clear cell renal cell carcinoma (ccRCC) as part of a phase 1b/2 umbrella platform trial.
AMG 176/Gilteritinib Combo Shows Preclinical Activity in FLT3-ITD+ AML
April 12th 2021, 12:44pm
The combination of the selective MCL-1 inhibitor AMG 176 plus gilteritinib was found to synergistically target preclinical models of FLT3 internal tandem duplication–mutated acute myeloid leukemia.
Neratinib Plus Fulvestrant Fails to Meet Efficacy Threshold in ER+ Metastatic Breast Cancer
April 12th 2021, 12:16am
Neratinib in combination with fulvestrant was active in heavily pretreated patients with estrogen receptor-positive, metastatic breast cancer, although the clinical benefit rate did not meet the predefined efficacy criteria.
Tislelizumab/Sitravatinib Shows Early Antitumor Activity, Safety in Platinum-Resistant Epithelial Ovarian Cancer
April 11th 2021, 10:34pm
The combination of tislelizumab and sitravatinib demonstrated early antitumor activity and a manageable safety profile in patients with recurrent platinum-resistant epithelial ovarian cancer and were naïve to PD-1/PD-L1 inhibition.
Parsaclisib/Ruxolitinib Improves SVR and Symptom Burden in Myelofibrosis
April 11th 2021, 7:27pm
The combination of parsaclisib and ruxolitinib has resulted in the improvement of spleen volume reduction and symptom burden in patients with myelofibrosis who have previously experienced a suboptimal response to a standard dose of single-agent ruxolitinib.